Skip to main content
Toggle navigation
Login
Search
Home
Tweets by RAPS Euro Convergence 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Bellmann, Matthias
TÜV SÜD Product Service GmbH
Device Lifetime and Lifecycle Management
Location: Pearl 3
Matthias Bellmann
Favorite
Bojunga, Niels
Molecular Health GmbH
IVDR Transition: Quo Vadis? – the current reality
Location: Carmine & Charcoal
Niels Bojunga
Favorite
Bos, Gert
Qserve Group
Clinical Evaluation: Measurable Outcome Parameters: Much More Than a Requirement for an MDR-Complaint CER
Location: Pearl 2
Gert Bos
Favorite
MDCG 2022-14: Game-Changer or 'Shopping List' for MDR Implementation?
Location: Pearl 2
Gert Bos
Favorite
Medical Device Regulation in International Perspective: EU IMDRF Chair in 2023
Location: Pearl 3
Gert Bos
Favorite
Opening Plenary Session: Leveraging our joint clinical data: the new frontier - a debate on our dreams!
Location: Pearl 1 + 2 + 3
Gert Bos
Favorite
Real World Evidence...What Could Possibly go Wrong? A Clinician's Perspective
Location: Pearl 2
Gert Bos
Favorite
Boumard, Charlene
Veeva MedTech
Sponsored Presentations: Streamlining Regulatory Affairs: Industry trends & Innovations
Location: Carmine & Charcoal
Charlene Boumard
Favorite
Bouygues, Christelle
EMA
Conversations That Matter: Interactions with Health Authorities
Location: Pearl 1 + 2 + 3
Christelle Bouygues
Favorite
MDR Art. 117 for Combination Products After 2 years. Still the same? State of Play from EMA, NB and Industry
Location: Pearl 2
Christelle Bouygues
Favorite
Bridgens, Joshua
DePuy Synthes (J&J)
Real World Evidence...What Could Possibly go Wrong? A Clinician's Perspective
Location: Pearl 2
Joshua Bridgens
Favorite
Brown, Phil
UKCA: challenges and opportunities
Location: Pearl 3
Phil Brown
Favorite
Bujar, Magdalena
CIRS
Regulatory policies and guidelines – are these enabling timely development of Orphan medicines globally?
Location: Pearl 1
Magdalena Bujar
Favorite
